17-β-estradiol reduces surface PD-L1 expression in estrogen receptor-positive breast cancer but not type 1 endometrial cancer cells (Letter)
File version
Version of Record (VoR)
Author(s)
Gu, Wenyi
Jeffery, Penny
Chen, Chen
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Abstract
We report here that 17-β-estradiol (E2), through ERα (estrogen receptor α), inhibits IFN-γ-induced surface PD-L1 (programmed death-ligand 1, CD274) level in advanced ER+/HER2− breast cancer (BC) but not in triple negative BC (TNBC) or endometrial cancer (EC). This study implies that mTOR and MAPK pathways can reduce the surface PD-L1 level and diminish immune evasion via ERα. It also has important implications on endocrine resistance and the limitations of mTOR or MAPK-targeted therapies for treating advanced ER+/HER2– BC.
Journal Title
Clinical and Translational Medicine
Conference Title
Book Title
Edition
Volume
13
Issue
7
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Item Access Status
Note
Access the data
Related item(s)
Subject
Nursing
Persistent link to this record
Citation
Li, H; Gu, W; Jeffery, P; Chen, C, 17-β-estradiol reduces surface PD-L1 expression in estrogen receptor-positive breast cancer but not type 1 endometrial cancer cells (Letter), Clinical and Translational Medicine, 2023, 13 (7), pp. e1330